International Congress on the Future of Breast Cancer East | Conference

Dr. Gradishar on the Significance of Drug Development in HER2+ Breast Cancer

July 21st 2021

William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.

Novel Vaccine Combos Represent a Promising Treatment Approach in Breast Cancer

July 19th 2021

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

July 19th 2021

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

SERDs Represent the Next Generation of ER-Targeting Therapy in Breast Cancer

July 19th 2021

Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer.

Chemoimmunotherapy Shakes Up Metastatic and Early-Stage TNBC

July 17th 2021

Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.

Tolaney Spotlights Tailoring Therapy by Risk in HER2+ Breast Cancer

July 16th 2021

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

Dr. Kalinsky on Therapeutic Options Beyond Chemotherapy in High-Risk Breast Cancer

July 16th 2021

Kevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.

Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Cancer

July 17th 2020

Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.

Dr. Mamounas on Recurrence Rates in Breast Cancer

July 17th 2020

Terry P. Mamounas, MD, MPH, FACS, discusses common recurrence rates in breast cancer.

Key Data Inform Treatment Decisions in Early HER2+ Breast Cancer

July 17th 2020

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

July 17th 2020

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach

July 17th 2020

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.